In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction

• Sandra Silva-Arrieta,

  Affiliation IrsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol, Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain

  ⨯
• Philip J. R. Goulder,

  Affiliations Department of Paediatrics, University of Oxford, Oxford, United Kingdom, HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa, Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, United States of America

  ⨯
• Christian Brander

  * E-mail: cbrander@irsicaixa.es

  Affiliations IrsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol, Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain, University of Vic–Central University of Catalonia, Catalonia, Vic, Spain, Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain

  http://orcid.org/0000-0002-0548-5778

  ⨯